Supernus Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 652
- Market Cap
- $1.9B
- Website
- http://www.supernus.com
- Introduction
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT00772603
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT00626236
- Locations
- 🇺🇸
Florida Clinical Research Center, Bradenton, Florida, United States
🇺🇸Sarkis Clinical Trials, Gainesville, Florida, United States
🇺🇸CNS Healthcare, Orlando, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath